Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single shot of your own stem cells ease knee arthritis?

NCT ID NCT02838069

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a single injection of a patient's own fat-derived stem cells can reduce pain and improve knee function in people with mild to moderate knee osteoarthritis that hasn't responded to other treatments. One hundred participants received either a low dose, a high dose, or a placebo injection. Researchers measured pain and function improvements over 6 to 24 months using questionnaires and MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a patient's own fat-derived stem cells (called mesenchymal stromal cells)
What this could lead to
If it works, this could offer a new, one-time injection to ease pain and improve knee function for people with mild to moderate osteoarthritis.
What could go wrong
This is a mid-stage trial with only 100 participants, so results may not apply to everyone. The treatment is still experimental, and long-term safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

100 people

The number who actually took part.

Started

Sep 2016

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Symptomatic mild to moderate osteoarthritis (OA) of the index knee as defined by the American college of Rheumatology (ACR) * Must meet pain criteria at the time of screening/baseline visit since at least half of the days in the previous month * NSAID washout of at least 2 days before screening/baseline Exclusion Criteria: * Previous treatments acting on cartilage or bone metabolism * Received intra-articular injection of corticosteroids, platelet rich plasma or hyaluronic acid within the previous 6 months, * Significant trauma or surgery to the index knee within the last year or arthroscopy of the index knee within 12 months of screening. * Kellgren-Lawrence Grade 1 or 4 in the index knee on any incidences. * Osteoarthritis causing significant pain in any joint other than the identified knee, i.e., pain in hip, or contralateral knee (≥ 20 mm pain) as confirmed by a separate VAS at baseline for any other painful joint concerned * History of joint replacement of the knee or hip within the previous 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis

Contacts and locations

Locations

  • UH Montpellier

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.